Inicio


Publicación

Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era


Información de la publicación

Información de la publicación
Tipo de publicación

Científica

Tipología

Investigación y estudios

Medio de publicación

Impreso: Artículos de investigación científica o tecnológica T1

Resumen

 New therapeutic alternatives have been developed in the last years for the treatment of multidrug-resistant Gram-positive infections. Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are considered a therapeutic challenge due to failures and lack of reliable antimicrobial options. Despite concerns related to the use of vancomycin in the treatment of severe MRSA infections in specific clinical scenarios, there is a paucity of solid clinical evidence that support the use of alternative agents (when compared to vancomycin). Linezolid, daptomycin and tigecycline are antibiotics approved in the last decade and newer cephalosporins (such as ceftaroline and ceftobiprole) and novel glycopeptides (dalvavancin, telavancin and oritavancin) have reached clinical approval or are in the late stages of clinical development. This review focuses on discussing these newer antibiotics used in the "post-vancomycin" era with emphasis on relevant chemical characteristics, spectrum of antimicrobial activity, mechanisms of action and resistance, as well as their clinical utility.

Autores

Rincón S1, Panesso D1, Díaz L1, Carvajal LP1, Reyes J2, Munita JM3, Arias CA1.

DOI Artículo Digital http://https://www.ncbi.nlm.nih.gov/pubmed/24968051
Fecha de publicación 04 de abril de 2014
Fecha de aceptación 21 de julio de 2017
Medio indexado (nombre)

Biomédica

Información de contacto

Contacto de Publicaciones